SEKHRI PAUL J

Row 1 · 2020-01-02 · Grant · Acquired 7,650 · Balance 7,650

F1: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant.

F2: 1/12th of the shares subject to the option become vested and exercisable on February 2, 2020 and 1/12th of the shares subject to the option shall vest monthly thereafter.

Row 1 · 2026-08-03 · Purchase · Acquired 12,500 · Balance 12,500

Row 2 · 2026-08-03 · Disposition to issuer · Disposed 169,468 · Balance 0

F1: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of Common Stock.

F2: One-third of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after June 1, 2026, and the remainder of the shares vest and become exercisable in substantially equal quarterly installments for a period of 24 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

Row 3 · 2026-08-03 · Grant · Acquired 169,468 · Balance 169,468

F1: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of Common Stock.

F2: One-third of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after June 1, 2026, and the remainder of the shares vest and become exercisable in substantially equal quarterly installments for a period of 24 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

Row 4 · 2026-07-30 · Grant · Acquired 155,558 · Balance 155,558

F2: One-third of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after June 1, 2026, and the remainder of the shares vest and become exercisable in substantially equal quarterly installments for a period of 24 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

Row 5 · 2026-08-03 · Disposition to issuer · Acquired 155,558 · Balance 0

F1: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of Common Stock.

F2: One-third of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after June 1, 2026, and the remainder of the shares vest and become exercisable in substantially equal quarterly installments for a period of 24 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

Row 6 · 2026-08-03 · Grant · Acquired 155,558 · Balance 155,558

F1: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of Common Stock.

F2: One-third of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after June 1, 2026, and the remainder of the shares vest and become exercisable in substantially equal quarterly installments for a period of 24 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

Row 7 · 2026-07-30 · Grant · Acquired 22,238 · Balance 22,238

F3: The shares subject to such option vest and become exercisable in substantially equal monthly installments for a period of 36 months after July 30, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date.

Row 8 · 2026-08-03 · Disposition to issuer · Disposed 22,238 · Balance 0

F1: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of Common Stock.

F3: The shares subject to such option vest and become exercisable in substantially equal monthly installments for a period of 36 months after July 30, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date.

Row 9 · 2026-08-03 · Grant · Acquired 22,238 · Balance 22,238

F1: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of Common Stock.

F3: The shares subject to such option vest and become exercisable in substantially equal monthly installments for a period of 36 months after July 30, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date.

Row 1 · 2022-05-19 · Grant · Acquired 40,000 · Balance 40,000

F1: This option shall vest and become exercisable in twelve equal quarterly installments following the grant date.

Row 1 · 2016-12-09 · Exercise / conversion · Acquired 175,000 · Balance 175,000

Row 2 · 2016-12-09 · Purchase · Acquired 43,750 · Balance 43,750

F2: The Reporting Person acquired the reported Warrants in a private sale transaction for cash consideration in the amount of $0.08 per warrant.

F1: The Common Stock Purchase Warrants (the "Warrants") are exercisable immediately.

Row 3 · 2016-12-09 · Other · Acquired 175,000 · Balance 175,000

F3: Pursuant to an Offer to Amend and Exercise launched by the Issuer on October 28, 2016 (as subsequently amended, the "Offering"), the exercise price of each Warrant tendered in the Offering was reduced to $0.50 per Warrant, and participants in the Offering received four shares for each Warrant tendered rather than one share. Pursuant to the terms of the Offering, the expiration date of tendered Warrants was accelerated to December 9, 2016. The Reporting Person tendered all of the Warrants beneficially owned in the Offering.

F1: The Common Stock Purchase Warrants (the "Warrants") are exercisable immediately.

Row 4 · 2016-12-09 · Exercise / conversion · Disposed 175,000 · Balance 0

F3: Pursuant to an Offer to Amend and Exercise launched by the Issuer on October 28, 2016 (as subsequently amended, the "Offering"), the exercise price of each Warrant tendered in the Offering was reduced to $0.50 per Warrant, and participants in the Offering received four shares for each Warrant tendered rather than one share. Pursuant to the terms of the Offering, the expiration date of tendered Warrants was accelerated to December 9, 2016. The Reporting Person tendered all of the Warrants beneficially owned in the Offering.

F1: The Common Stock Purchase Warrants (the "Warrants") are exercisable immediately.

Row 1 · 2024-12-02 · Disposition to issuer · Disposed 25,461 · Balance 0

F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of 10/14/2024, by and among Longboard Pharmaceuticals, Inc. (the "Issuer"), H. Lundbeck A/S ("Parent"), Lundbeck LLC ("Payor"), and Langkawi Corporation ("Purchaser"), on 12/02/2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger").

F2: On such date and at such time as the certificate of merger in respect of the Merger was duly filed with the Secretary of State of the State of Delaware in accordance with the DGCL (the "Effective Time"), pursuant to the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option as of immediately prior to the Effective Time multiplied by (ii) the excess of (x) $60.00 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes.

Row 2 · 2024-12-02 · Disposition to issuer · Disposed 12,367 · Balance 0

F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of 10/14/2024, by and among Longboard Pharmaceuticals, Inc. (the "Issuer"), H. Lundbeck A/S ("Parent"), Lundbeck LLC ("Payor"), and Langkawi Corporation ("Purchaser"), on 12/02/2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger").

F2: On such date and at such time as the certificate of merger in respect of the Merger was duly filed with the Secretary of State of the State of Delaware in accordance with the DGCL (the "Effective Time"), pursuant to the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option as of immediately prior to the Effective Time multiplied by (ii) the excess of (x) $60.00 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes.

Row 3 · 2024-12-02 · Disposition to issuer · Disposed 12,500 · Balance 0

F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of 10/14/2024, by and among Longboard Pharmaceuticals, Inc. (the "Issuer"), H. Lundbeck A/S ("Parent"), Lundbeck LLC ("Payor"), and Langkawi Corporation ("Purchaser"), on 12/02/2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger").

F2: On such date and at such time as the certificate of merger in respect of the Merger was duly filed with the Secretary of State of the State of Delaware in accordance with the DGCL (the "Effective Time"), pursuant to the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option as of immediately prior to the Effective Time multiplied by (ii) the excess of (x) $60.00 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes.

Row 4 · 2024-12-02 · Disposition to issuer · Disposed 22,500 · Balance 0

F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of 10/14/2024, by and among Longboard Pharmaceuticals, Inc. (the "Issuer"), H. Lundbeck A/S ("Parent"), Lundbeck LLC ("Payor"), and Langkawi Corporation ("Purchaser"), on 12/02/2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger").

F2: On such date and at such time as the certificate of merger in respect of the Merger was duly filed with the Secretary of State of the State of Delaware in accordance with the DGCL (the "Effective Time"), pursuant to the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option as of immediately prior to the Effective Time multiplied by (ii) the excess of (x) $60.00 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes.

Row 1 · 2021-07-28 · Purchase · Acquired 12,500 · Balance 12,500

F1: The common stock and common stock warrant were acquired in the issuer's registered direct offering of units, in which each unit consisted of one share of common stock and one common stock warrant to purchase 0.75 of a share of common stock, at a price of $4.00 per unit. The price paid per unit is reflected in Table I.

Row 2 · 2021-07-28 · Purchase · Acquired 9,375 · Balance 9,375

F1: The common stock and common stock warrant were acquired in the issuer's registered direct offering of units, in which each unit consisted of one share of common stock and one common stock warrant to purchase 0.75 of a share of common stock, at a price of $4.00 per unit. The price paid per unit is reflected in Table I.

F2: The common stock warrant will be exercisable six months after the date of issuance, at an exercise price of $5.00 per share and will expire five years from the date such warrant first becomes exercisable.

Row 1 · 2026-09-01 · Exercise / conversion · Acquired 460 · Balance 15,651

F1: Transaction exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act.

Row 2 · 2026-09-01 · Exercise / conversion · Disposed 460 · Balance 1,381

F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Class A Common Stock of the Issuer.

F1: Transaction exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act.

F3: On June 17, 2026, the Reporting Person was granted 1,841 RSUs under the Issuer's Amended & Restated 2013 Equity Incentive Plan, of which 1/4 of the RSUs vested on September 1, 2026, with the remaining RSUs vesting equally on a quarterly basis thereafter, subject to continued service on the Issuer's board of directors on the applicable vesting date.

Row 1 · 2026-02-17 · Grant · Acquired 140,000 · Balance 392,212

F1: The options vest 25% on the first anniversary of the grant date and in quarterly equal installments thereafter.